Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: The end of the affair with gene therapy

This article was originally published in Scrip

Executive Summary

The End of the Affair, a 1951 novel by Graham Greene, depicts some of the worst human emotions that can accompany the ending of a relationship, and then after a break of two years, the re-ignition of those emotions in an investigative post-mortem. Way back at the start of this century I invested in a gene therapy company. Although the inevitable end of the affair caused me some heartache, unlike the principal characters in Mr Greene's classic novel I found it a valuable cathartic learning experience to have lost some money in this unproven area of biotechnology.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel